Correction: Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial
Per‑Ola Carlsson, Daniel Espes, Sofia Sisay, Lindsay C. Davies, C. I. Edvard Smith, Mathias G. Svahn
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPancreatic function and diabetes
Correction: Diabetologia (2023) 66:1431-1441
10.1007/s00125-023-05934-3
Unfortunately, two entries were incorrect in Table 2. The proportion of participants in the high-dose group with IA-2 antibodies 1 year post treatment was incorrectly reported as 2/3 instead of 1/3. Similarly, the proportion of participants in the same group with GAD65 or IA-2 autoantibodies was incorrectly reported as 3/3 instead of 2/3. The authors are confident that these errors do not compromise the study design, analysis, interpretation or conclusions. The corrected table is shown here. The original article has been corrected.
Table 2. Characteristics pre treatment and 1 year post treatment with ProTrans for participants included in part A of the studyCharacteristicPre treatment1 year post treatmentLow dose (N=3)Medium dose (N=3)High dose (N=3)Low dose (N=3)Medium dose (N=3)High dose (N=3)GAD65 (n/N)2/32/3^a^2/32/32/32/3IA-2 (n/N)2/31/3^a^1/32/31/31/3GAD65 and IA-2 (n/N)1/31/3^a^1/31/31/31/3GAD65 or IA-2 (n/N)3/32/3^a^2/33/32/32/3HbA_1c_ (mmol/mol)42 ± 544 ± 1247 ± 1443 ± 241 ± 1240 ± 4HbA_1c_ (%)6.0 ± 0.76.2 ± 1.76.5 ± 1.96.1 ± 0.35.9 ± 1.75.8 ± 0.6Glucose (mmol/l)6.1 ± 0.96.4 ± 1.36.7 ± 0.26.3 ± 1.16.6 ± 1.96.8 ± 0.4Time above optimal glucose range (%)^b^21 ± 1529 ± 2331 ± 732 ± 1534 ± 3035 ± 11Time within optimal glucose range (%)^b^68 ± 752 ± 1367 ± 843 ± 1144 ± 1657 ± 8Time below optimal glucose range (%)^b^10 ± 919 ± 192 ± 125 ± 2121 ± 238 ± 4Insulin (U/day)26.2 ± 16.323.8 ± 4.723.1 ± 9.922.8 ± 9.535.7 ± 9.517.6 ± 4Insulin (U kg^−1^ day^−1^)0.33 ± 0.150.30 ± 0.080.31 ± 0.130.28 ± 0.130.45 ± 0.130.23 ± 0.05Fasting C-peptide (nmol/l)0.31 ± 0.010.27 ± 0.010.26 ± 0.10.28 ± 0.090.19 ± 0.020.31 ± 0.07MMTT AUC C-peptide (nmol/l) 2 h1.07 ± 0.340.60 ± 0.070.67 ± 0.130.79 ± 0.320.55 ± 0.140.63 ± 0.06MMTT C-peptide max (nmol/l) 2 h1.6 ± 0.70.9 ± 0.11.0 ± 0.21.0 ± 0.40.7 ± 0.20.9 ± 0.1Data are presented as median ± SD^a^Data from one of the participants from visit 4^b^Optimal range was defined as 4.4–7.2 mmol/l